An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For Pain Associated With Diabetic Peripheral Neuropathy
Latest Information Update: 27 Jan 2021
At a glance
- Drugs Pregabalin (Primary)
- Indications Diabetic neuropathies; Neurogenic pain
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 20 Sep 2018 New trial record
- 21 Feb 2008 Status changed from not yet recruiting to recruiting.